Skip to main
OBIO

OBIO Stock Forecast & Price Target

OBIO Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Orchestra BioMed Hldgs is a promising biomedical company due to their accelerated technology, risk-reward sharing partnerships with medical device companies, and promising product candidates such as AVIM Therapy and Virtue SAB for the treatment of hypertension and atherosclerosis. The company has a strong financial outlook with significant cash reserves, expected revenue from partnerships and acquisitions, and accelerating enrollment in their clinical trials. While there is limited human clinical data at this time, the company's roadmap to FDA approval and potential commercial milestones make it a buy with a 12-month price target of $20.

Bears say

Orchestra BioMed Hldgs is facing a number of risks and uncertainties that could potentially impact its financial performance and ability to bring its product candidates to market. These include commercialization risk, competition from larger companies, limited human clinical data, dependence on external financing, and potential failure of intellectual property protection. While there are potential opportunities for the company, such as an expanded target patient population and Breakthrough Device designation, it is important to consider the potential challenges and risks in the overall outlook for the stock.

OBIO has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orchestra BioMed Holdings Inc (OBIO) Forecast

Analysts have given OBIO a Strong Buy based on their latest research and market trends.

According to 5 analysts, OBIO has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orchestra BioMed Holdings Inc (OBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.